Liquidia licenses Vectura's nebulizer device for treprostinil L606 in US PAH/PH-ILD

Liquidia Corp

Upfront payment $2M; development milestones up to $12M; sales milestones up to $92.5M.
Royalties in mid-single digits; Vectura to manufacture and supply the device.
Exclusive US rights for treprostinil products treating hypertension and interstitial lung diseases (PAH, PH-ILD).
Rights of first negotiation for additional territories and indications during term.
Term until expiration of Royalty Term; termination for material breach, discontinuation, or patent challenge.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.